Copyright © Inderes 2011 - present. All rights reserved.

Ambu

67.40 DKK

-0.59 %

Less than 1K followers

AMBU B

NASDAQ Copenhagen

Medical Equipment & Services

Health Care

-0.59 %
-6.26 %
-25.24 %
-23.41 %
-33.66 %
-42.83 %
-31.20 %
-78.92 %
+6,902.60 %

Ambu is active in medical technology. The company develops and markets diagnostic equipment for actors in healthcare. The largest activity is found in the development of solutions for endoscopy, gastroscopy and patient monitoring. Operations are held on a global level with the largest presence in Europe and North America. Ambu was founded in 1937 and is headquartered in Ballerup, Denmark.

Read more
Market cap
18.15B DKK
Turnover
2.07M DKK
Revenue
6.04B
EBIT %
12.99 %
P/E
29.43
Dividend yield-%
0.61 %
Revenue and EBIT-%

Revenue B

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
6.5
2026

Interim report Q2'26

26.8
2026

Interim report Q3'26

5.11
2026

Annual report '26

ShowingAll content types
HCA Morgenbørs 08/04 - Udsigt til festdag på aktiemarkedet efter våbenhvile i Mellemøsten
Video by
Rasmus Køjborg, Victor Skriver

HCA Morgenbørs 08/04 - Udsigt til festdag på aktiemarkedet efter våbenhvile i Mellemøsten

I dagens Morgenbørs ser vi ind i meget positive aktiemarkeder med plusser på 3-6% ovenpå udsigten til våbenhvile i Mellemøsten. Herhjemme fokus på bl.a. Vestas, Novo Nordisk og NTG.

FLSmidth & Co.A.P. Møller - MærskNTG Nordic Transport GroupAmbuINVISIOTormHafniaD/S NordenTrifork GroupVestas Wind SystemsJyske BankRockwoolCarlsberg

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Forum discussions
Today, the Q4 interim report for FY2019/20 was released. The endoscope business grew by 81% and accounted for 48% of the company’s revenue during the fiscal year. Growth is expected to continue at a good level. In terms of units, 1.085 million endoscopes were sold, and sales of 1...
11/11/2020, 9:39 AM
by Mikko Kiesiläinen
4
However, even this company made its biggest profit ever in 2025 (it probably increased by about 2.5 times from 2024), and revenue is growing very predictably (year after year). I think the decline experienced in the stock is just a correction of the high valuation of previous years...
3/20/2026, 7:21 AM
2
Since the thread has been dead for years, I dare to ask silly questions even with shaky knowledge. Has anyone more knowledgeable followed the endoscopy market in recent years? What does the competitive situation look like now that healthcare has returned to normal times? When I looked...
3/19/2026, 1:11 PM
by Zoltan
2
Salkunrakentaja has an article about this: SalkunRakentaja – 21 Aug 21 Tanskalainen Ambu kasvaa vauhdilla uusien tuotteiden siivittämänä Sairaaloiden ja pelastuslaitosten laitevalmistaja Ambu saa Handelsbankenilta ostosuosituksen. Yhtiöön kohdistuu kovat kasvuodotukset. The article...
8/22/2021, 6:04 AM
by Ruudolf
1
Q3 was released a few days ago: Investor Relations Still seems expensive. Growth has stumbled a bit this year. It would be interesting to know more precisely why, and whether the problems are temporary.
8/22/2021, 4:09 AM
by Taavetti
1
Ambu’s results will be out tomorrow. The valuation level is certainly dizzying. With the numbers for the 2021E financial year ending in September, the EV/EBITDA is 89.4x. If there is a disappointment tomorrow, the drop could be significant.
1/26/2021, 8:37 AM
by Mikko Kiesiläinen
1
Last week, Ambu announced that its single-use cystoscope had received regulatory approval for the European market. This is one of the 12 devices that Ambu has promised to bring to market by 2022. Tomorrow, the quarterly report will be released. The impact of the coronavirus brings...
11/10/2020, 12:13 PM
by Mikko Kiesiläinen
1
Read more on our forum
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.